Clarity expands pipeline in breast cancer with Cu-64/67 SAR-trastuzumab: Pre-clinical data published and trastuzumab supply agreement in place
Sydney, Australia 11 February 2025 Highlights Clarity renews its focus on the breast cancer market, spearheaded by 64/67Cu-SAR-trastuzumab and reinforced by its SAR-Bombesin, SARTATE and SAR-bisPSMA products in this indication. It is estimated that 316,950 women will be diagnosed with invasive breast cancer in 2025 in the United States (US), with 42,170 dying from the disease1.…